Inhibitory efficacy in platelet aggregation and pharmacokinetics of single oral administration of 300mg clopidogrel and 20mg prasugrel
- Conditions
- Ischemic heart diseases with PIC
- Registration Number
- JPRN-UMIN000014161
- Lead Sponsor
- Kazuo Umemura Center for clinical research Hamamatsu University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 50
Not provided
1.History of liver diseases, cardiovascular diseases, respiratory diseaases, gastroenteric diseases, kidney diseases, cerebralvascular diseases, cancer 2.Known hypersensitivity to some drugs and foods 3.Under normal range in platelet counts at screning 4.Treatment by other doctors (included supplement) within 14 days before screening 5.Treatment with any investigational compound within 120 days before screening 6.History of blood taken *>= 1200ml of all blood within 1 year before screening *>= 400ml of all blood with 84 days before screening *>= 200ml of all blood within 14 days before screening 7.Known active chronic hepatitis B or C, active syphilis and human immunodeficiency virus infection 8.Abuse of alcohol or drugs (included past history) 9.Bleeding, in the tendency to bleeding, and family history and past history of bleeding disorders 10.During pregnancy and possibility of pregnancy and lactation period 11.Any serious medical or psychiatric illness that could, in the opinion of the investigator, potentially interfere with the completion of treatment according to this protocol.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pharmacodynamics of clopidogrel and prasugrel
- Secondary Outcome Measures
Name Time Method Pharmacokinetics of clopidogrel and prasugrel